Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$2.88 USD
+0.08 (2.86%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.88 USD
+0.08 (2.86%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Zacks News
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 9.09% and 2.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 52.63% and 52.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
by Zacks Equity Research
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -11.11% and 2.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -50% and 12.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Xeris (XERS) Might Surprise This Earnings Season
by Zacks Equity Research
Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
by Zacks Equity Research
Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.
Taro Pharmaceutical (TARO) Tops Q2 Earnings Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of 111.11% and 8.03%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 6.90% and 3.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -14.81% and 4.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab
by Zacks Equity Research
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lannett (LCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lannett (LCI) delivered earnings and revenue surprises of 8.70% and 10.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -11.68% and 11.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 0% and 66.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 34.44% and 93.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -2.56% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?